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Objectives:We evaluated the effectiveness of pentoxifylline, knitted viscose or hydrocolloid dressings, and single-layer or
four-layer bandaging for venous ulceration.
Method:A factorial randomized controlled trial with 24-week follow-upwas conducted in leg ulcer clinics in Scotlandwith
blinded allocation to pentoxifylline (1200 mg) or placebo, knitted viscose or hydrocolloid dressings, and single-layer or
four-layer bandages. The study enrolled 245 adults with venous ulcers. The main outcome measure was time to complete
healing. Secondary outcomes included proportions healed, withdrawals, and adverse events. Analysis was by intention to
treat.
Results: There was no evidence of interaction between the drug, bandages, and dressings. Pentoxifylline was associated
with nonsignificant increased ulcer healing (62% vs 53%; P .21). Four-layer bandages were associated with significantly
higher healing rates (67% vs 49%; P .009). There was no difference in healing between knitted viscose and hydrocolloid
dressings (58% and 57%; P  .88). Cox regression models increased the significance of the pentoxifylline effect (relative
risk of healing, 1.4; 95% confidence interval, 1.0 to 2.0).
Conclusions: Pentoxifylline increased the proportion healing compared with placebo to the same extent as shown in recent
systematic reviews, although this finding was only statistically significant when a secondary adjusted analysis was
conducted. Four-layer bandaging produced higher healing rates than single-layer bandaging. There was no difference in
time to healing between knitted viscose and hydrocolloid dressings. ( J Vasc Surg 2007;45:134-41.)Leg ulceration is a chronic, recurring condition affect-
ing about 1% of the adult population in industrialized
countries.1,2 Most ulcers are secondary to venous insuffi-
ciency; others are due to arterial insufficiency, diabetes
mellitus, rheumatoid arthritis, and connective tissue disor-
ders. The primary functional abnormality in venous ulcer-
ation is ambulatory venous hypertension caused by venous
reflux or obstruction that gives rise to changes at the tissue
level, including white cell trapping, capillary tufting, and
pericapillary fibrin cuffs.3 Externally applied compression,
such as bandages, stockings, or pneumatic boots, reduces
venous hypertension and promotes healing.4
A systematic review has found that compression heals
more ulcers than dressings alone.4 It has not been possible,
From the School of Healthcare, University of Leedsa; Lothian and Forth
Valley Leg Ulcer Studyb; and the Medical Statistics Unit,c and Depart-
ment of Surgery,d University of Edinburgh.
Supported by ConvaTec UK Ltd, Hoeschst Roussel Ltd UK, Chief Scientist
Office, Scotland.
Competition of interest: This trial was partly funded by the distributors of
pentoxifylline (Hoechst), hydrocolloid dressings (Convatec), and the
single layer bandage (Convatec), but the analysis and writing were con-
ducted independently.
Correspondence: E. Andrea Nelson, PhD, RN, School of Healthcare, Baines
Wing, University of Leeds, Leeds LS2 9UT UK (e-mail: e.a.nelson@leeds.
ac.uk).
0741-5214/$32.00
Copyright © 2007 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2006.09.043
134however, to determine the dose-response relationship be-
tween compression levels and healing rates, and whether,
for example, multiple layers of bandage are necessary.4
Four-layer bandaging is widely used but it can be bulky,
and we sought to compare it with a single-layered bandage
that can supply and sustain high levels of pressure.5
Ulcer management includes wound dressings to pre-
vent bandages from adhering to the wound and to provide
a moist environment for wound healing.6 Modern dress-
ings such as hydrocolloids promote moist wound healing
by restricting moisture loss from the wound. The role of
such semi-occlusive dressings in venous ulcers is unclear,
however, because bandages also restrict moisture loss,7 and
amoist wound environment can thus be achieved with a dry
dressing. Hydrocolloids cost more and have higher rates of
contact sensitivity than simple dressings8; therefore, we set
out to compare the relative effectiveness of knitted viscose
and hydrocolloid dressings.
Another goal was to determine whether adjuvant ther-
apy of sustained release pentoxifylline (oxpentifylline) with
compression and dressings would increase healing rates, as
four previous trials in 247 people receiving compression did
not provide conclusive results,9-12 and one trial found a
statistically significant benefit with pentoxifylline.10
A factorial trial design allows examination of the inter-
action between interventions and comparison of a number
of independent interventions with no increase in trial size.
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comparisons to answer these questions efficiently and in a
manner that allowed for the identification of interactions
between elements of treatment.13
METHODS
We undertook a 2  2  2 factorial trial of pentoxifyl-
line, dressings, and bandages for venous and arterial ulcers.
The methods and the results of the evaluation of pentoxi-
fylline for 200 simple venous ulcers included in this trial
report are described elsewhere.13,14 In brief, we showed
that complete healing occurred in 65 (64%) of 101 patients
receiving pentoxifylline and in 52 (53%) of the 99 patients
receiving placebo. This difference in the healing rates did
not reach statistical significance.
This report reflects the factorial nature of the study
design and describes the results for all three interventions
for simple and nonsimple venous ulcers and, therefore,
reports interactions between treatments, results of the
dressing comparison, and results of the bandage compari-
son, and includes an additional 45 participants and fully
reports on adverse events and withdrawals.
Study population. People18 years old with clinical
signs of venous disease (lipodermatosclerosis, varicose ec-
zema, and varicose veins) were considered for the trial if
they had been clinically diagnosed as having a venous leg
ulcer of at least 1cm in length and 8 weeks’ duration.
Exclusion criteria were:
● Significant arterial disease (ankle-brachial pressure in-
dex 0.8)
● Diabetes mellitus
● Pregnant or lactating women
● Premenopausal women not using contraceptives
● Known concurrent severe illness; for example, myocar-
dial infarction or renal failure
● Sensitivity to methylxanthines or caffeine containing
drinks
● Taking warfarin, steroids, oxpentifylline, oxerutins, or
naftidrofuryl
● Life expectancy 6 months




● Unable or unwilling to provide written, informed
consent
Recruitment and randomization. We recruited 245
patients with venous leg ulcers treated in the community or
as outpatients from two centers in Scotland. After written
informed consent was obtained, sealed, sequentially num-
bered, opaque envelopes were used to allocate participants
to placebo or pentoxifylline, knitted viscose or hydrocolloid
dressings, and four-layer or adhesive single-layer bandages.
There was no lead-in phase, but patients were recruited
from community services with widespread use of high
compression. Randomization was stratified by clinical cen-
ter and simple/nonsimple venous disease using permutedblocks of length 8. The nonsimple group was defined as
participants either with seropositive rheumatoid arthritis or
in whom venous pathology was not confirmed on exami-
nation using hand-held Doppler. In planning the trial, we
believed it important not to presume that people with
seropositive rheumatoid arthritis would have the same
prognosis as people without because theymay, for example,
have cutaneous vasculitis, skin fragility, and venous disease;
hence, we stratified participants by its presence.15
Both patients and nurses were aware of the allocated
bandage and dressing treatment after assignment. Pentoxi-
fylline or placebo tablets were supplied from the pharmacy
in numbered containers; therefore, clinicians and patients
were unaware of the allocation to active or placebo tablet.
Intervention. All ulcers were cleansed using tap water
and the skin moisturized with arachis or olive oil. Experi-
enced trial nurses renewed dressings and bandages weekly,
or more frequently if required.
Drug. Pentoxifylline (oxpentifylline), sustained-release
400-mg tablets, three times daily, or identical placebos.
Dressing. Hydrocolloid dressing (HCD), Granuflex E
(ConvaTec UK Ltd), also known as Duoderm CGF, or
knitted viscose dressing (KVD) NA (Johnson & Johnson
UK Ltd).
Bandages. Either a four-layer bandage or a single-layer
adhesive bandage (SLB) was used. The four-layer bandages
were applied using the Charing Cross technique.16 The
single-layer bandage was a hydrocolloid lined, woven, elas-
tomeric, adhesive, Ace-type bandage applied in a figure-8
technique from toe to knee.
Data collection. Nurses completed a dressing log at
each leg ulcer dressing visit, which recorded whether or not
an ulcer was healed, the date of each visit, the condition of
the periulcer skin, and any adverse events. Follow-up of all
participants continued from randomization to complete
ulcer healing or for 24 weeks. The primary end point was
time to complete healing of all ulcers on the reference
leg. Secondary outcomes included proportion of patients
healed at 24 weeks, withdrawals, and adverse events. A
healed ulcer was defined as complete epithelial cover in the
absence of a scab.
Sample size calculation and statistical analysis.
Using a conservative estimate of 40% of ulcers healed at 24
weeks with four-layer bandage or KVD based on previous
trials4 and assuming a 20% absolute increase in ulcers healed
would be clinically important, we calculated that at least 200
patients (100 in each of two treatments) would give us 80%
power to detect this difference at 24 weeks (2  5%).
The primary analysis was by intention to treat, and we
reported healing to 6 months for everyone irrespective of
compliance with treatment. Those without evidence of
healing at the time they were last seen were considered
failures at the end of follow-up. Compliance with treatment
was assessed as a separate outcome. Our analyses (R. J. P.)
compared the proportions with complete healing of all
ulcers on the reference leg between individuals randomized
to pentoxifylline or placebo, either bandage system, or
either dressing.
dage.
JOURNAL OF VASCULAR SURGERY
January 2007136 Nelson et alWe plotted the data for time to healing as Kaplan-Meier
curves and conducted an unadjusted analysis using a Cox
proportional hazards model, comparing the time to healing
between people randomized to the comparator interven-
tions. We also conducted a secondary adjusted analysis
utilizing prognostic information collected before random-
ization because this usually gives more precise estimates of
treatment effects. Initially, a model was fitted including all
three main treatment comparisons and all possible treat-
ment interactions. Interactions among treatments were
later dropped from the model, which was refitted with and
without a set of covariates. Logistic regression was used to
assess treatment withdrawal rates.
RESULTS
Of 525 people assessed, we recruited 245 with ve-
Fig 1. Allocation to trial treatments; drug, dressing, and
dressing; 4LB, four-layer bandage; SLB, single-layer ban
Table I. Baseline characteristics in the trial groups by drug
Intervention
Drug†
Pentoxifylline Placebo P‡ Knitte
Center A/B 50/71 52/72 .99 52
Sex: male/
female
36/85 44/80 .41 37
Walks freely/
not
43/78 42/82 .89 38
Simple venous/
not simple
101/20 99/25 .57 98
Age (years) 71.0  11.4 69.0  11.3 .10 69.7 
73 (35-91) 69 (34-93) 71 (35
Weight (kg) 78.7  18.6 77.9  22.6 .31 78.1 
76 (40-148) 72 (41-174) 74 (40
Reference ulcer
Area (mm2) 1005  2609 705  1178 .71 910 
378 (50-26311) 395 (54-10118) 359 (63
Duration
(months)
14.3  28.8 11.7  26.0 .35 14.8 
5.0 (2-204) 4.0 (2-240) 6.5 (2-
Episodes since
first ulcer
2.5  2.5 3.3  3.9 .09 2.8 
2 (1-15) 2 (1-20) 2 (1-
Years since first
ulcer
9.2  12.0 10.0  12.1 .42 9.1 
3 (0-52) 5 (0-56) 5 (0-
*Significance tests applied to a comparison of baseline characteristics of the
are presented in parenthesis to emphasise that the usual interpretation of
randomization.
†Data are presented as numbers for listed for categoric variables; and contin
‡Mann Whitney U test/2.nous ulcers (simple and nonsimple) during a 40-monthperiod. Fig 1 shows the distribution of allocation to
drug, dressing, and bandage. Table I presents the base-
line descriptive data for the 245 trial participants by
intervention (drug, dressing, and bandage). Overall,
there were two women for every man in the trial, and the
average age was 70. Ulcers were open for a median of 5
months before trial entry and had a median area of just
less than 400 mm2. Overall, ulcers healed within the trial
period in 141 (58%) of 245 participants. The propor-
tions of people healing within each of the trial groups are
provided in Table II.
Unadjusted analyses. An initial analysis with a Cox
proportional hazards model fitting the effect of drug, ban-
dages, dressings, and all possible interactions, gave no
suggestion of any interactions among the treatments on
time to healing (all interaction values for P  .14). Conse-
age.KVD, knitted viscose dressing;HCD,Hydrocolloid
essing and bandage allocation*
Dressing† Bandage†
ose Hydrocolloid P‡ Single layer Four-layer P‡
50/77 .54 53/75 49/68 .99
43/84 .78 39/89 41/76 .53
47/80 .51 49/79 36/81 .27
102/25 .70 103/25 97/20 .74
70.3  12.0 .33 71.5  10.3 68.3  12.2 .05
71 (34-92) 73 (46-93) 68 (34-91)
78.5  21.1 .79 76.2  18.9 80.5  22.3 .21
) 75 (41-174) 74 (40-154) 76 (42-174)
0 794  1210 .28 1025  2637 661  879 .85
11) 404 (50-10118) 385 (54-26311) 393 (50-5560)
11.3  25.0 .17 11.1  17.3 15.1  35.2 .78
4.0 (2-204) 5.0 (2-96) 5.0 (2-240)
3.0  3.3 .79 2.9  3.2 2.9  3.5 .53
2 (1-20) 2 (1-20) 2 (1-20)
10.0  13.3 .44 9.5  11.9 9.7  12.2 .74
3 (0-56) 5 (0-56) 4 (0-52)
mized groups are reported to comply with common reporting practice, but
es does not apply, as the null hypothesis is known to be true because of




















uousquently, each mode of treatment is presented separately,
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including all three treatment effects.
Drug. Of the 121 people randomized to pentoxifyl-
line, 75 healed (62%), and in the placebo group, 66 (53%)
of 124 healed (2c  1.58, P  .21). Kaplan-Meier esti-
mates for median time to healing were 98 days for pentoxi-
fylline and 118 for placebo (Fig 2). Analysis of time to
healing using a Cox proportional hazards model, including
the effect of drug, bandages, and dressings, gave an esti-
mated hazard ratio for healing with pentoxifylline com-
pared with placebo of 1.3 (95% confidence interval [CI],
0.9 to 1.8; P  .12).
Dressing. Of those allocated to the KVD group, 58%
(69/118) healed compared with 57% (72/127) in the
HCDgroup (2c 0.02, P .88). Kaplan-Meier estimates
for median time to healing were 99 days in HCD and 127
Table II. Healing rate in each group of the trial at 24
weeks
Drug Dressing Bandage Healing (%)
Pentoxifylline Knitted viscose Single layer 16/33 (48)
4 layer 20/25 (80)
Hydrocolloid Single layer 18/31 (58)
4 layer 21/32 (66)
Placebo Knitted viscose Single layer 16/33 (48)
4 layer 17/27 (63)
Hydrocolloid Single layer 13/31 (42)
4 layer 20/33 (60)
Pentoxifylline — — 75/121 (62)
Placebo- — — 66/124 (53)
Knitted viscose — 69/118 (58)
— Hydrocolloid — 72/127 (57)
— — Single layer 63/128 (49)
— — 4 layer 78/117 (67)
Fig 2. Survival curve for drug: pentoxifylline (blue line) or pla-
cebo (green line).in KVD (Fig 3). Cox proportional hazards model gave anestimated hazard ratio for healing with KVD compared
with HCD of 1.1 (95% CI, 0.8 to 1.6; P  .53).
Bandage. Of those in the four-layer bandage group,
67% healed completely (78/117) compared with 49% (63/
128) in those in the single-layer bandage group (2c 
6.92, P  .009). Kaplan-Meier estimates for median time
to healing were 78 days in the four-layer bandage group
and 168 days in the single-layer bandage group (Fig 4). The
Cox proportional hazards model also indicated that the
difference in healing rates was statistically significant (P 
.001), with the hazard ratio for healing for those with a
four-layer bandage group compared with a single-layer
Fig 3. Survival curve for dressing: knitted viscose (blue line) or
hydrocolloid (green line).
Fig 4. Survival curve for bandage: single-layer (blue line) or four-
layer (green line).bandage estimated as 1.8 (95% CI, 1.3 to 2.5).
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portional hazards model to identify other factors that may
influence healing as well as the interventions being evalu-
ated. This analysis also takes into account any imbalances in
the distribution of prognostic variables between the groups.
Although randomization of patients avoids systematic bias
with respect to prognostic variables, it is likely that, by chance,
there will be some imbalance in the groups. Within this
model, we incorporated terms for the drug, dressing, ban-
dage, center, and simple or nonsimple venous ulceration,
because these were intrinsic to the study design. We also
included area (obtained by acetate tracing and blinded area
scanning) and duration of current ulceration in view of
their widely accepted prognostic importance. We examined
the other variables recorded in the data set and on the basis
of their significance. Also included was years since the first
ulcer categorized as 0-1 years, and so on. The model is
presented in Table III.
This shows that area of the ulcer had the most impact
on the subsequent ulcer healing relative to those in the
lowest quartile (ulcer area, 50 to 180 mm2); the relative
rate of healing in the next three quartiles were 52%, 35%,
Table III. Cox proportional hazard model: hazard of
healing with prognostic factors
Variables N HR 95% CI P
Drug
Placebo 124 1 .046
Pentoxifylline 121 1.4 1.01, 2.01
Dressing
Hydrocolloid 127 1 .75
Knitted viscose 118 1.1 0.74, 1.5
Bandage
Single layer 128 1 .0005
Four layer 117 2 1.4, 2.9
Center
B 143 1 .45
A 102 1.2 0.80, 1.7
Type of ulcer
Simple 200 1 .89
Not-simple 45 0.97 0.61, 1.5
Area (based on quartiles)
mm2
50-180 61 1 .0005
181-390 60 0.52 0.33, 0.80
391-760 60 0.35 0.21, 0.56
761  60 0.19 0.11, 0.34
Missing 4 0.2 0.03, 1.5
Ulcer history (years since
first ulcer)
0-1 91 2.4 1.4, 4.1
2-5 46 1.9 1.0, 3.6
6-15 50 2.5 1.4, 4.4
16 58 1 0.01
Ulcer duration in months
2 56 1.4 0.72, 2.9
3-4 60 1.8 0.97, 3.5
5-7 37 1.1 0.54, 2.4
8-12 49 1.8 0.95, 3.5
13 43 1 0.017
HR, Hazard ratio; CI, confidence interval.and 19% compared with the lowest quartile.The next most important variable was the bandage
applied, where the relative healing rate with the four-layer
bandage compared with the single-layer bandage was 2.0
(95% CI, 1.4 to 2.9; P  .0005).
The number of years since first ulceration was also
statistically significant. Relative to individuals with 16
years’ history of ulceration, all other categories showed an
approximate doubling of the healing rate. Duration of
reference ulcer has been found to be prognostic in other
studies, and this was confirmed in this study, with the worst
rate of healing in those with the longest ulcer duration.
Neither the center, the dressing applied, nor whether
the ulcer was simple or not had any effect on healing.
In this model, pentoxifylline is just significant at the
conventional 5% level, with a relative healing rate of 1.4
(95% CI, 1.0 to 2.0). Other models examined with nonsig-
nificant terms dropped from our model resulted in the
significance level for pentoxifylline varying across the com-
monly used cutoff value of P  .05.
Adverse events. A similar number of adverse events
occurred in the two groups: 97 patients in the pentoxifyl-
line group reported 245 adverse events (treatment related
and unrelated), and 90 patients in the placebo group re-
ported 246 adverse events. Most events were reports of
ulcer deterioration, infection, and digestive upsets. Serious
adverse events described as unrelated to the study medica-
tion were recorded for 16 people in the pentoxifylline
group: skin ulceration in 3 patients, bone fracture, surgery,
stroke, coronary thrombosis, syncope, skin carcinoma, cel-
lulitis, heart and kidney failure, hostility, accidental over-
dose, myocardial infarction, and aggravation of rheumatoid
arthritis. In four patients, serious adverse events were de-
scribed as possibly related to the treatment: hematemesis,
reduced platelet count, gastric upset, and gastrointestinal
hemorrhage. Ten serious adverse events described as unre-
lated to the study medication were recorded for eight
people in the placebo group: lack of healing, heart failure in
3 patients, cholecystitis, skin carcinoma, cerebral ischemia,
skin aggravation, myocardial infarction, and urinary reten-
tion.
Withdrawals. Although all effectiveness analyses were
performed on an intention-to-treat basis, it is interesting to
look at how many people continued to use the allocated
intervention. We recorded withdrawals from drug therapy,
bandages, and dressings.
Drugs. There were 34 withdrawals from each arm of
the trial. These were due to serious adverse events (4 in
pentoxifylline group), other adverse reactions (23 in pen-
toxifylline, 27 in placebo group), development of exclusion
criteria for the trial (4 pentoxifylline, 2 placebo) or an
intercurrent illness developed (3 pentoxifylline, 5 placebo)
that required withdrawal from the study.
Bandages and dressings. We considered withdrawals
from bandage and dressing together because the perfor-
mance of one intervention (eg, absorption capacity) could
potentially influence the acceptability of the other. Sixty-
eight people withdrew from their original bandage or dress-
ing allocation, or both. Reasons for withdrawal included
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withdrew from both bandage and dressing (not necessarily
at the same time), 27 withdrew from the bandage alone,
and 15 from the dressing alone (Table IV,). KVD was
associated with a 36% withdrawal rate (42/118), with 20%
requiring a change in dressing; HCD had a 20% (26/127)
withdrawal rate, with 14% requiring a change in dressing.
Of the 128 people allocated to single-layer bandage, 36
(28%) had a bandage change compared with 17 (15%) in
the four-layer bandage group.
Logistic regression investigating the chance of with-
drawing from bandage demonstrated that both bandage
and dressing predicted withdrawal. The interaction be-
tween the dressing and bandage was statistically significant
(P  .001), indicating that a combination of KVD and
single-layer bandage results in a higher withdrawal rate
than would be anticipated from their individual withdrawal
rates. With this combination, 25 (38%) of 66 patients did
not continue with their bandage, compared with 11 (18%)
of 62, 10 (15%) of 65, and 7 (13%) of 52 with the other
bandage/dressing combinations. A further six patients
with this combination changed their dressings, producing
an overall noncompletion rate of 47%.
DISCUSSION
The trial has a number of strengths, and these include
the simultaneous evaluation of the effects of three treat-
ment modalities used in the treatment of venous ulcers.
This is, to our knowledge, the first factorial trial in venous
ulcers to simultaneously evaluate dressings, bandages, and
adjuvant drug therapy. The factorial design allowed us to
examine the relationship between drugs, dressings, and
bandages in venous ulcer healing. Because venous ulcer
treatment always requires bandages and dressings as a min-
imum, this design means we could test for the presence of
interaction, such as whether a dressing was less effective in
the presence of a particular bandage. This is theoretically
possible because the ulcer environment and, hence, ulcer
Table IV. Estimates of effectiveness from randomized con
wearing high compression
Scenario Trials Participants (n












*Measure of statistical heterogeneity.healing may be influenced by both dressings and bandages.Multiple layers of bandages reduce water vapor loss from
ulcers and therefore act as semi-occlusive dressings.7
Although there was no suggestion of interaction be-
tween interventions on rates of healing on the intention-
to-treat analysis, the combination of dressings and bandage
did affect rates of withdrawal from treatment. The single-
layer bandage and the knitted viscose dressing, when used
together, may not have been sufficiently absorbent and led
tomaceration. The combinations used currently have layers
of wool padding to absorb wound exudates to prevent skin
damage and maceration.
If there had been an interaction between the three
interventions for healing, then we would not have been
able to make straight comparisons. This, however, would
have been an interesting finding in itself: that the effect of
one element of leg ulcer treatment can be affected by
selection of another element.
Research nurses in two sites undertook the bandaging
and data collection with one coordinator to ensure that
compression-bandaging techniques were comparable be-
tween centers and throughout the study. We used time to
healing as our main outcome measure rather than propor-
tions healed at a specific time point, and this conveys speed
of healing as well as number achieving healing. In addition,
we defined healing as complete healing of all ulcers on the
leg being monitored because this is more meaningful than
the healing of an isolated, reference ulcer.
The trial was adequately powered to detect a clinically
meaningful difference, and it monitored people for 6
months, sufficiently long to detect healing in almost 60% of
the population. To reduce selection bias, allocation was
concealed by using sealed, opaque, sequentially numbered
envelopes. Having a placebo intervention for the drug,
rather than making a comparison against standard care,
ensured that performance bias did not influence the results
of this comparison.
We have reported in detail the withdrawal from ban-
dages and dressings, in contrast to many previous trials. In
ed trials of pentoxifylline (1200 mg) vs placebo in people
Pooled relative risk of
healing (random effects) 95% CI I2*
1.51 0.91, 2.48 45.50%
1.32 1.01, 1.72 36.80%troll
)addition, we did not arbitrarily exclude people with large
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the effect of intervention in this hard-to-heal group.
Limitations. The limitations of the study included the
lack of verification of venous pathology using duplex ultra-
sound evaluation before trial entry. At the time the trial was
set up, it was not possible to arrange this for all potential
trial patients before trial entry, although many did have a
vascular assessment during the study. A trained nurse used
a hand-held Doppler at recruitment to assess the presence
of venous insufficiency, but this is less reliable than duplex.
Given that many patients are treated for venous ulceration
after clinical assessment, this limitation reflects the reality of
current clinical practice. This means we cannot confirm the
importance of saphenous patency for clinical outcomes.
A further limitation is the lack of blinding of nurses,
clinicians, or outcome assessment with regards to bandages
and dressings. It is not possible to easily mask these inter-
ventions. We were not able to use photographs for blinded
outcome assessment because the skin was marked by the
dressings and bandages in such a manner that experienced
clinicians could determine which dressing or bandage had
been used; for example, the skin surrounding ulcers treated
with hydrocolloid, compared with an embossed appearance
underneath a woven dressing.
People taking warfarin were excluded from the trial
because pentoxifylline is contraindicated in this situation;
therefore, this limits the generalizability of our trial because
some people with venous ulcers will be taking warfarin.
Because we have no evidence that warfarin is a prognostic
factor for healing, it is not clear whether our trial popula-
tion differs from the larger population to any significant
extent.
We have reported both an unadjusted and an adjusted
Cox proportional hazards model. At the outset of the study
we envisaged the primary analysis would be the unadjusted
one, but the adjusted model includes prognostic variables
and hence is capable of producing additional insights. The
final model is dependent on associations found in the data,
and because there is the possibility of choosing the model
to best fit with preconceptions, we also reported the unad-
justed analysis.
How our results fit in with other findings. Eight
other trials have compared simple dressings (eg, gauze or
knitted viscose) with hydrocolloid dressings. Seven of these
found no evidence of benefit; the eighth, which did find a
difference, had imbalanced groups at randomization.17
We have been able to identify two other randomized
controlled trials comparing single-layer and four-layer ban-
dages.18,19 These trials were small, involving 44 partici-
pants, and neither used survival analysis. Both reported no
difference in healing rates but were too small to exclude
anything but a massive difference in healing rates.
A systematic review of five trials (404 people) evaluat-
ing 1200 mg pentoxifylline as an addition to compression
concluded that it is associated with higher healing rates,
although it just reaches statistical significance at the con-
ventional 5% level (relative risk of healing with pentoxifyl-
line, 1.31;95% CI, 1.00 to 1.74; random effects, I237.7%).20 Summary data from 200 ulcers from this trial are,
however, included in this estimate. Table IV summarizes
the impact of adding the results from the 245 participants
of this trial to the previous four studies making this com-
parison (1200 mg vs placebo, all wearing compression).
This trial doubles the population considered, increasing the
precision of the estimate. Without this trial, the relative risk
of healing with pentoxifylline is 1.51 (95% CI, 0.91 to
2.48), and by adding our study, this becomes 1.32 (95%
CI, 1.01 to 1.72). These pooled results suggest the prob-
ability of a venous ulcer healing in 6 months is increased by
32% by adding 1200 mg of pentoxifylline to a regimen of
compression therapy.
Pentoxifylline is a generic drug, and we found similar
numbers withdrawing from the trial in both groups,
hence it appears to be well tolerated. The effect size is
moderate but may be considered to be clinically worth-
while because treatment is simple and inexpensive. An
absolute difference in healing rates of 9% translates to a
number needed to treat of 12 over 6 months. This number
needed to treat means that for every 12 people treated with
pentoxifylline, one additional person would heal by 6
months. The improvement in healing rate from 53% to 62%
with pentoxifylline is certainly smaller than the 49% to 63%
reported in one randomized controlled trial of an engi-
neered human skin equivalent.21 This trial was not de-
signed to follow-up patients to recurrence to determine the
effect of pentoxifylline on the durability of healing, and this
question remains unanswered.
Implications for clinical practice. We found no ben-
efit for hydrocolloid dressings compared with knitted
viscose dressings when venous ulcers are treated with
high-compression bandaging. Given the higher cost of
hydrocolloid dressings compared with simple dressings,
and the lower allergic and irritant potential for simple,
low-adherent dressings, then these are preferred.
CONCLUSION
Patients with venous ulcers treated with four-layer
compression are significantly more likely to heal than
those treated with an adhesive, single-layer bandage.
Adding oral pentoxifylline (1200 mg daily) to a regimen
of high-compression therapy may increase the chance of
healing in line with recent overviews, but this finding is
analysis dependent.
We thank the participants for taking part in the trial,
district nurses and hospital outpatient staff for recruiting
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and research nurses at the centers for coordinating local
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